机构：[1]Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China中山大学附属第一医院[2]Tradit Chinese Med Hosp Guangdong Prov, Guangzhou, Peoples R China广东省中医院[3]Zhongshan City Peoples Hosp, Zhongshan, Peoples R China[4]Cent Hosp Guangdong Prov Agr Reclamat, Zhanjiang, Guangdong, Peoples R China
第一作者机构：[1]Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China[2]Tradit Chinese Med Hosp Guangdong Prov, Guangzhou, Peoples R China[3]Zhongshan City Peoples Hosp, Zhongshan, Peoples R China[4]Cent Hosp Guangdong Prov Agr Reclamat, Zhanjiang, Guangdong, Peoples R China
推荐引用方式(GB/T 7714)：
Peng Jianjun,Li Yong,Xiao Jianjun,et al.A multicenter, open-label phase II trial of secondline apatinib plus irinotecan in patients with advanced gastric cancer[J].JOURNAL OF CLINICAL ONCOLOGY.2022,40(4):doi:10.1200/JCO.2022.40.4_suppl.287.
APA：
Peng, Jianjun,Li, Yong,Xiao, Jianjun&Liu, Huaqiang.(2022).A multicenter, open-label phase II trial of secondline apatinib plus irinotecan in patients with advanced gastric cancer.JOURNAL OF CLINICAL ONCOLOGY,40,(4)
MLA：
Peng, Jianjun,et al."A multicenter, open-label phase II trial of secondline apatinib plus irinotecan in patients with advanced gastric cancer".JOURNAL OF CLINICAL ONCOLOGY 40..4(2022)
医学